Literature DB >> 19925797

PDE4 inhibitor upregulates PTH-induced osteoclast formation via CRE-mediated COX-2 expression in osteoblasts.

Hyojung Park1, A Long Sae Mi No, Jung-Min Lee, Ling Chen, Soo Young Lee, Dong-Seok Lee, Mijung Yim.   

Abstract

We investigated the interplay between parathyroid hormone (PTH) and phosphodiesterases (PDEs) in osteoblasts. PDE4 negatively regulated PTH-induced cAMP accumulation. PDE4 inhibitor enhanced PTH-induced osteoclast formation and RANKL mRNA expression, which is partially mediated by COX-2 mRNA expression. Two CRE sites in the COX-2 promoter were required for the increase in COX-2 transcription by PDE4 inhibitor, and the expression of a dominant-negative form of CREB abolished COX-2 mRNA expression in response to PDE4 inhibitor or PTH in osteoblasts. Taken together, our data indicate that PDE4 inhibitor promotes PTH-induced osteoclast formation partially via CRE-mediated COX-2 mRNA expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19925797     DOI: 10.1016/j.febslet.2009.11.043

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

Review 1.  Cellular communications in bone homeostasis and repair.

Authors:  Ken-Ichi Nakahama
Journal:  Cell Mol Life Sci       Date:  2010-08-08       Impact factor: 9.261

2.  Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats.

Authors:  D Peter; R Göggel; F Colbatzky; P Nickolaus
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

Review 3.  Control of bone remodeling by the peripheral sympathetic nervous system.

Authors:  Florent Elefteriou; Preston Campbell; Yun Ma
Journal:  Calcif Tissue Int       Date:  2013-06-14       Impact factor: 4.333

4.  Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.

Authors:  Angela Pennisi; Wen Ling; Xin Li; Sharmin Khan; Yuping Wang; Bart Barlogie; John D Shaughnessy; Shmuel Yaccoby
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

Review 5.  Altered bone biology in psoriatic arthritis.

Authors:  Homaira Rahimi; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

6.  IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.

Authors:  Tue W Kragstrup; Mary Adams; Søren Lomholt; Morten A Nielsen; Line D Heftdal; Peter Schafer; Bent Deleuran
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-02-22       Impact factor: 5.346

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.